The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Patterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study
Open accessAbstract
BACKGROUND: Immune infiltration of breast tumours is associated with clinical outcome. However, past work has not accounted for the diversity of functionally distinct cell types that make up the immune response. The aim of this study was to determine whether differences in the cellular composition of the immune infiltrate in breast tumours influence survival and treatment response, and whether these effects differ by molecular subtype. METHODS AND FINDINGS: We applied an established computational approach (CIBERSORT) to bulk gene expression profiles of almost 11,000 tumours to infer the proportions of 22 subsets of immune cells. We investigated associations between each cell type and survival and response to chemotherapy, modelling cellular proportions as quartiles. We found that tumours with little or no immune infiltration were associated with different survival patterns according to oestrogen receptor (ER) status. In ER-negative disease, tumours lacking immune infiltration were associated with the poorest prognosis, whereas in ER-positive disease, they were associated with intermediate prognosis. Of the cell subsets investigated, T regulatory cells and M0 and M2 macrophages emerged as the most strongly associated with poor outcome, regardless of ER status. Among ER-negative tumours, CD8+ T cells (hazard ratio [HR] = 0.89, 95% CI 0.80-0.98; p = 0.02) and activated memory T cells (HR 0.88, 95% CI 0.80-0.97; p = 0.01) were associated with favourable outcome. T follicular helper cells (odds ratio [OR] = 1.34, 95% CI 1.14-1.57; p < 0.001) and memory B cells (OR = 1.18, 95% CI 1.0-1.39; p = 0.04) were associated with pathological complete response to neoadjuvant chemotherapy in ER-negative disease, suggesting a role for humoral immunity in mediating response to cytotoxic therapy. Unsupervised clustering analysis using immune cell proportions revealed eight subgroups of tumours, largely defined by the balance between M0, M1, and M2 macrophages, with distinct survival patterns by ER status and associations with patient age at diagnosis. The main limitations of this study are the use of diverse platforms for measuring gene expression, including some not previously used with CIBERSORT, and the combined analysis of different forms of follow-up across studies. CONCLUSIONS: Large differences in the cellular composition of the immune infiltrate in breast tumours appear to exist, and these differences are likely to be important determinants of both prognosis and response to treatment. In particular, macrophages emerge as a possible target for novel therapies. Detailed analysis of the cellular immune response in tumours has the potential to enhance clinical prediction and to identify candidates for immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Bonnefoi, H., Potti, A., Delorenzi, M., Mauriac, L., Campone, M., Tubiana-Hulin, M., Petit, T., Rouanet, P., Jassem, J., Blot, E., et al. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70345-5 · Cited by 212
RetractedPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040296 · Cited by 23,020
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., & Vandenbroucke, J. P. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61602-x · Cited by 21,320
Robust enumeration of cell subsets from tissue expression profiles
Newman, A. M., Liu, C. L., Green, M. R., Gentles, A. J., Feng, W., Xu, Y., Hoang, C. D., Diehn, M., & Alizadeh, A. A. (2015) · Nature Methods · doi:10.1038/nmeth.3337 · Cited by 13,224
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
voom: precision weights unlock linear model analysis tools for RNA-seq read counts
Law, C. W., Chen, Y., Shi, W., & Smyth, G. K. (2014) · Genome Biology · doi:10.1186/gb-2014-15-2-r29 · Cited by 6,155
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
Self-citationLehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., Bonnefoi, H., Cameron, D., Gianni, L., Valagussa, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62422-8 · Cited by 4,742
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
Molecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,560
The prognostic landscape of genes and infiltrating immune cells across human cancers
Gentles, A. J., Newman, A. M., Liu, C. L., Bratman, S. V., Feng, W., Kim, D., Nair, V. S., Xu, Y., Khuong, A., Hoang, C. D., et al. (2015) · Nature Medicine · doi:10.1038/nm.3909 · Cited by 3,118
Multiple Imputation of Missing Values
Royston, P. (2004) · The Stata Journal: Promoting communications on statistics and Stata · doi:10.1177/1536867x0400400301 · Cited by 2,340
Denkert, C., Loibl, S., Noske, A., Roller, M., Müller, B. M., Komor, M., Budczies, J., Darb-Esfahani, S., Kronenwett, R., Hanusch, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.7370 · Cited by 1,762
DeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., Gallagher, W. M., Wadhwani, N., Keil, S. D., Junaid, S. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0028 · Cited by 1,715
Shimizu, J., Yamazaki, S., & Sakaguchi, S. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.10.5211 · Cited by 1,491
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Nanda, R., Chow, L. Q. M., Dees, E. C., Berger, R., Gupta, S., Geva, R., Pusztai, L., Pathiraja, K., Aktan, G., Cheng, J. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8931 · Cited by 1,477
Ries, C. H., Cannarile, M. A., Hoves, S., Benz, J., Wartha, K., Runza, V., Rey-Giraud, F., Pradel, L. P., Feuerhake, F., Klaman, I., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.016 · Cited by 1,384
Adams, S., Gray, R. J., Demaria, S., Goldstein, L., Perez, E. A., Shulman, L. N., Martino, S., Wang, M., Jones, V. E., Saphner, T. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.55.0491 · Cited by 1,299
Loi, S., Michiels, S., Salgado, R., Sirtaine, N., Jose, V., Fumagalli, D., Kellokumpu-Lehtinen, P.-L., Bono, P., Kataja, V., Desmedt, C., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu112 · Cited by 1,256
Macrophage polarization in tumour progression
Sica, A., Larghi, P., Mancino, A., Rubino, L., Porta, C., Totaro, M. G., Rimoldi, M., Biswas, S. K., Allavena, P., & Mantovani, A. (2008) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2008.03.004 · Cited by 1,241
Blows, F. M., Driver, K. E., Schmidt, M. K., Broeks, A., van Leeuwen, F. E., Wesseling, J., Cheang, M. C., Gelmon, K., Nielsen, T. O., Blomqvist, C., et al. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000279 · Cited by 1,116
Self-citationCancer immunoediting from immune surveillance to immune escape
Kim, R., Emi, M., & Tanabe, K. (2007) · Immunology · doi:10.1111/j.1365-2567.2007.02587.x · Cited by 1,074
CD4+ follicular helper T cell infiltration predicts breast cancer survival
Gu-Trantien, C., Loi, S., Garaud, S., Equeter, C., Libin, M., de Wind, A., Ravoet, M., Le Buanec, H., Sibille, C., Manfouo-Foutsop, G., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67428 · Cited by 1,070
Onizuka, S., Tawara, I., Shimizu, J., Sakaguchi, S., Fujita, T., & Nakayama, E. (1999) · PubMed · Cited by 1,062
Denkert, C., von Minckwitz, G., Brase, J. C., Sinn, B. V., Gade, S., Kronenwett, R., Pfitzner, B. M., Salat, C., Loi, S., Schmitt, W. D., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.1967 · Cited by 1,026
Using the outcome for imputation of missing predictor values was preferred
Moons, K. G. M., Donders, R. A. R. T., Stijnen, T., & Harrell, F. E. (2006) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2006.01.009 · Cited by 994
Inappropriate use of bivariable analysis to screen risk factors for use in multivariable analysis
Sun, G.-W., Shook, T. L., & Kay, G. L. (1996) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(96)00025-x · Cited by 933
Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers
Saito, T., Nishikawa, H., Wada, H., Nagano, Y., Sugiyama, D., Atarashi, K., Maeda, Y., Hamaguchi, M., Ohkura, N., Sato, E., et al. (2016) · Nature Medicine · doi:10.1038/nm.4086 · Cited by 871
Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes
Desmedt, C., Haibe-Kains, B., Wirapati, P., Buyse, M., Larsimont, D., Bontempi, G., Delorenzi, M., Piccart, M., & Sotiriou, C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4756 · Cited by 828
Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients
Ali, H. R., Provenzano, E., Dawson, S.-J., Blows, F. M., Liu, B., Shah, M., Earl, H. M., Poole, C. J., Hiller, L., Dunn, J. A., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu191 · Cited by 774
Self-citationTeschendorff, A. E., Miremadi, A., Pinder, S. E., Ellis, I. O., & Caldas, C. (2007) · Genome Biology · doi:10.1186/gb-2007-8-8-r157 · Cited by 497
Self-citationLeukocyte composition of human breast cancer
Ruffell, B., Au, A., Rugo, H. S., Esserman, L. J., Hwang, E. S., & Coussens, L. M. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1104303108 · Cited by 479
Association of the Autoimmune Disease Scleroderma with an Immunologic Response to Cancer
Joseph, C. G., Darrah, E., Shah, A. A., Skora, A. D., Casciola-Rosen, L. A., Wigley, F. M., Boin, F., Fava, A., Thoburn, C., Kinde, I., et al. (2014) · Science · doi:10.1126/science.1246886 · Cited by 436
Strachan, D. C., Ruffell, B., Oei, Y., Bissell, M. J., Coussens, L. M., Pryer, N., & Daniel, D. (2013) · OncoImmunology · doi:10.4161/onci.26968 · Cited by 376
Cassier, P. A., Italiano, A., Gomez-Roca, C. A., Le Tourneau, C., Toulmonde, M., Cannarile, M. A., Ries, C., Brillouet, A., Müller, C., Jegg, A.-M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00132-1 · Cited by 364
Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types
Iglesia, M. D., Parker, J. S., Hoadley, K. A., Serody, J. S., Perou, C. M., & Vincent, B. G. (2016) · Journal of the National Cancer Institute · doi:10.1093/jnci/djw144 · Cited by 360
West, N. R., Milne, K., Truong, P. T., Macpherson, N., Nelson, B. H., & Watson, P. H. (2011) · Breast Cancer Research · doi:10.1186/bcr3072 · Cited by 356
A clinically relevant gene signature in triple negative and basal-like breast cancer
Rody, A., Karn, T., Liedtke, C., Pusztai, L., Ruckhaeberle, E., Hanker, L., Gaetje, R., Solbach, C., Ahr, A., Metzler, D., et al. (2011) · Breast Cancer Research · doi:10.1186/bcr3035 · Cited by 338
A Three-Gene Model to Robustly Identify Breast Cancer Molecular Subtypes
Haibe-Kains, B., Desmedt, C., Loi, S., Culhane, A. C., Bontempi, G., Quackenbush, J., & Sotiriou, C. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr545 · Cited by 313
Ali, H. R., Glont, S.-E., Blows, F. M., Provenzano, E., Dawson, S.-J., Liu, B., Hiller, L., Dunn, J., Poole, C. J., Bowden, S., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv192 · Cited by 304
Self-citationThe prognostic significance of B lymphocytes in invasive carcinoma of the breast
Mahmoud, S. M. A., Lee, A. H. S., Paish, E. C., Macmillan, R. D., Ellis, I. O., & Green, A. R. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1620-1 · Cited by 261
Genome-driven integrated classification of breast cancer validated in over 7,500 samples
Ali, H. R., Rueda, O. M., Chin, S., Curtis, C. N., Dunning, M., Aparicio, S. A. J. R., & Caldas, C. H. (2014) · Genome biology · doi:10.1186/preaccept-1094756427137059 · Cited by 225
Self-citationLohr, M., Edlund, K., Botling, J., Hammad, S., Hellwig, B., Othman, A., Berglund, A., Lambe, M., Holmberg, L., Ekman, S., et al. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.01.036 · Cited by 214
Coronella, J. A., Spier, C., Welch, M., Trevor, K. T., Stopeck, A. T., Villar, H., & Hersh, E. M. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.4.1829 · Cited by 171
Naturally occurring B-cell responses to breast cancer
Coronella-Wood, J. A., & Hersh, E. M. (2003) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-003-0409-4 · Cited by 161
Ali, H. R., Dariush, A., Provenzano, E., Bardwell, H. A., Abraham, J., Iddawela, M. Y., Vallier, A.-L., Hiller, L., Dunn, J., Bowden, S. J., et al. (2016) · Breast Cancer Research · doi:10.1186/s13058-016-0682-8 · Cited by 101
Self-citationVarn, F. S., Andrews, E. H., Mullins, D. W., & Cheng, C. (2016) · Nature Communications · doi:10.1038/ncomms10248 · Cited by 50
Cited by
Understanding the tumor immune microenvironment (TIME) for effective therapy
Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,409
The immune contexture in cancer prognosis and treatment
Fridman, W. H., Zitvogel, L., Sautès–Fridman, C., & Kroemer, G. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.101 · Cited by 2,263
Denkert, C., von Minckwitz, G., Darb-Esfahani, S., Lederer, B., Heppner, B. I., Weber, K. E., Budczies, J., Huober, J., Klauschen, F., Furlanetto, J., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30904-x · Cited by 2,157
Zhang, B., Wu, Q., Li, B., Wang, D., Wang, L., & Zhou, Y. L. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01170-0 · Cited by 943
Metadata
- Authors
- Ali, H. R., Chlon, L., Pharoah, P. D. P., Markowetz, F., & Caldas, C.
- Venue
- PLOS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-12-13
- Volume
- 13
- Issue
- 12
- Pages
- e1002194
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W2567668099
- Cited by
- 615
- References
- 54
- FWCI
- 11.65
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.